Test Price
2,800 AEDโ Home Collection Available
UCP2 Gene Hyperinsulinism (UCP2-Related) Genetic Test in UAE | AED 2800 | DHA Licensed
Executive Summary & Core Metrics
Executive Summary
This UCP2 genetic test provides high-precision NGS-based diagnosis for congenital hyperinsulinism, with 99.9% diagnostic sensitivity. The service includes a pre-test genetic consultation and post-test telephonic clinical guidance by DHA-licensed clinicians.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by DHA-licensed Medical Genetics Consultant.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The UCP2 Gene Hyperinsulinism NGS Test is a specialized genetic analysis that sequences the UCP2 gene to detect mutations responsible for congenital hyperinsulinism, a metabolic disorder causing severe hypoglycemia. The test employs Next-Generation Sequencing (NGS) with bioinformatics confirmation, ensuring full gene coverage including deep intronic variants.
| Feature | Our Test: NGS-based UCP2 Gene | Closest Alternative: Single-Gene Sanger Sequencing |
|---|---|---|
| Precision | 99.9% diagnostic sensitivity (full gene coverage, including deep intronic variants) | ~95% sensitivity; may miss copy number variations |
| Methodology | Next-Generation Sequencing (NGS) with bioinformatics confirmation | Sanger sequencing of coding exons only |
| Speed | 3โ4 Weeks | 6โ8 Weeks |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
"This UCP2 genetic test is essential for families facing hyperinsulinism. The NGS methodology offers a comprehensive view of genetic variants, which is crucial for guiding treatment decisions. Clinical correlation with fasting studies and pediatric endocrinology input remains mandatory to contextualize genetic findings."
Medication Advisory
Exclusion Criteria & Emergency Red Flags
- Individuals unable to provide informed consent or lacking legal guardian authorization.
- Patients with known bleeding disorders or severe anemia that contraindicate venous sampling.
- Any acute metabolic crisis (e.g., severe hypoglycemic coma) โ proceed directly to the nearest emergency department; do not wait for a genetic test.
- If the patient experiences seizures, loss of consciousness, or unresponsiveness, call 998 immediately.
Clinical Safety Compliance
Medication Warning: Do not discontinue any prescribed medication, including diazoxide or octreotide, without consulting your treating physician. Abrupt cessation can trigger life-threatening hypoglycemia.
Patient FAQ & Clinical Guidance
1. What does the UCP2 gene hyperinsulinism test detect?
This test uses NGS to detect mutations in the UCP2 gene that cause congenital hyperinsulinism, a condition driving recurrent hypoglycemia. The result aids in diagnosis, prognosis, and therapeutic planning for affected individuals.
2. How is the sample collected for this genetic test?
A small blood sample (whole blood) is collected by a certified phlebotomist. VIP Mobile Phlebotomy is available daily from 8 AM to 11 PM across Dubai and the UAE, with temperature-controlled cold-chain transport ensuring sample integrity.
3. What is the turnaround time and how will I receive results?
Results are available within 3โ4 weeks. You will receive a secure digital report with telephonic interpretation by a DHA-licensed Consultant Medical Genetics, who will explain findings and clinical implications.
UAE Regulatory & Data Privacy Adherence
This genetic testing service complies fully with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. Our DHA facility license number 1143 and ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139) ensure regulatory compliance and data security.
Clinical & Logistical Metadata
| Test Name | UCP2 Gene Hyperinsulinism (UCP2-Related) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3โ4 Weeks |
| Sample Type / Matrix | Whole Blood |
| Methodology Used | Next-Generation Sequencing (NGS) with Bioinformatics Confirmation |
| ICD-10-CM Code | P70.1 (Hyperinsulinism of newborn) |
| LOINC Code | 82386-1 (UCP2 gene mutation analysis in Blood) |
| DHA Facility License & Laboratory Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians